Abstract
The sepsis syndrome represents an improper immune response to pathogens and is associated with an unacceptably high rate of mortality. Although supportive care is of benefit to the septic patient, there are no viable therapeutics available that target the immune system suitable for the whole septic population. Recently, using a physiologically relevant murine mouse model, the cannabiniod 2 receptor has been shown to play a critical role in the host response to sepsis. Here, the structure, expression, signaling, and function of the CB2 receptor on leukocytes will be reviewed. Further, the effects mediated by the CB2 receptor during sepsis will be reviewed. Altogether, alterations in inflammation and the host response during sepsis by the CB2 receptor support its use as a possible therapeutic agent.
Keywords: Neutophils, macrophages, T cells, B cells, inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: The Cannabinoid 2 Receptor as a Potential Therapeutic Target for Sepsis
Volume: 10 Issue: 3
Author(s): Kevin Richard Kasten, Johannes Tschop, Matthias Hans Tschop and Charles Curtis Caldwell
Affiliation:
Keywords: Neutophils, macrophages, T cells, B cells, inflammation
Abstract: The sepsis syndrome represents an improper immune response to pathogens and is associated with an unacceptably high rate of mortality. Although supportive care is of benefit to the septic patient, there are no viable therapeutics available that target the immune system suitable for the whole septic population. Recently, using a physiologically relevant murine mouse model, the cannabiniod 2 receptor has been shown to play a critical role in the host response to sepsis. Here, the structure, expression, signaling, and function of the CB2 receptor on leukocytes will be reviewed. Further, the effects mediated by the CB2 receptor during sepsis will be reviewed. Altogether, alterations in inflammation and the host response during sepsis by the CB2 receptor support its use as a possible therapeutic agent.
Export Options
About this article
Cite this article as:
Richard Kasten Kevin, Tschop Johannes, Hans Tschop Matthias and Curtis Caldwell Charles, The Cannabinoid 2 Receptor as a Potential Therapeutic Target for Sepsis, Endocrine, Metabolic & Immune Disorders - Drug Targets 2010; 10 (3) . https://dx.doi.org/10.2174/187153010791936874
DOI https://dx.doi.org/10.2174/187153010791936874 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Contribution of γδ T Cells to the Pathogenesis of EAE and MS
Current Molecular Medicine The Interplay between Indoleamine 2,3-Dioxygenase 1 (IDO1) and Cyclooxygenase (COX)-2 In Chronic Inflammation and Cancer
Current Medicinal Chemistry Immunotherapy for Conformational Diseases
Current Pharmaceutical Design Cannabinoid Receptor Type 2 Activation in Atherosclerosis and Acute Cardiovascular Diseases
Current Medicinal Chemistry Mesenchymal Cells in the Treatment of Spinal Cord Injury: Current & Future Perspectives
Current Stem Cell Research & Therapy Enhanced Anti-Amyloid Effect of Combined Leptin and Pioglitazone in APP/PS1 Transgenic Mice
Current Alzheimer Research Oxidative Stress and Neurodegenerative Diseases: A Neurotrophic Approach
Current Drug Targets The Biochemical Mechanisms of T-Cell Anergy
Current Immunology Reviews (Discontinued) Astroglial Connexins in Neurological and Neuropsychological Disorders and Radiation Exposure
Current Medicinal Chemistry Pixuvri<sup>®</sup> (Pixantrone Dimaleate, BBR 2778): From Lab to Market
Current Organic Chemistry CTLA-4Ig: Uses and Future Directions
Recent Patents on Inflammation & Allergy Drug Discovery Inhibition of MHC II Gene Transcription by Nitric Oxide and Antioxidants
Current Pharmaceutical Design Estrogens as Potential Therapeutic Agents in Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry Approaches Towards Better Immunosuppressive Agents
Current Topics in Medicinal Chemistry Altered Peptide Ligand Antagonism: From Immune Evasion to Immunotherapy
Drug Design Reviews - Online (Discontinued) Immune-Glutamatergic Dysfunction as a Central Mechanism of the Autism Spectrum Disorders
Current Medicinal Chemistry Small-Molecule Chemokine Receptor Antagonists: Potential Targets for Inflammatory and Allergic Disorders
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Immune Modulation by Plasmid DNA-mediated Cytokine Gene Transfer
Current Pharmaceutical Design Immunoglobulin Free Light Chains in Immune Responses
Current Immunology Reviews (Discontinued) The Long and Winding Road to Cancer Treatment: The Trail System
Current Pharmaceutical Design